All In Biotech

Drug Trial Radar · NCT00790218

A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma

A Phase 1-2, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered CF102 in Patients With Advanced Hepatocellular Carcinoma

Last checked: Nov 19, 2026Latest source record: May 17, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

19

Actual

Start

Feb 2009

Primary completion

Dec 2012

Study completion Dec 2013

Sponsor

Lead sponsor
Can-Fite BioPharmaIndustry
Sponsor type
Industry
First posted
Nov 13, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial will test the safety and efficacy of CF102 in patients with advanced liver cancer. Successive groups of patients will be given higher doses of CF102 by mouth on a twice-daily basis. Treatment will be assessed for adverse effects and for effects on the tumor.

Conditions

  • Hepatocellular Carcinoma

Interventions

  • CF102Drug

    CF102 capsules twice daily by mouth

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limiting ToxicityTime frame: From start of treatment until Day 28 of Cycle 1
  2. Maximum Tolerated DoseTime frame: first 28 days (Cycle 1)
  3. Maximum Plasma Concentration of CF102 (Cmax)Time frame: Dose Escalation Phase on Day 1 and Day 29 pre-dose and at 1, 2, 3, 4, 6, 8 hours post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Rabin Medical Center

    Tel Aviv, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.